Skip to content
Search

Latest Stories

'Real-world' UK data shows 70 per cent decline in Covid infections after first Pfizer shot

England’s coronavirus vaccine campaign is significantly reducing cases of Covid-19, with a drop of around 70 per cent in infections among healthcare workers who have had a first dose of the Pfizer-BioNTech shot, health officials said on Monday (Feb 22).

Data analysed by Public Health England (PHE) showed the Pfizer provided high levels of protection against infection and symptomatic disease from a single dose, and that hospitalisation and death from Covid-19 will be reduced by more 75 per cent in elderly people who have had a first dose.


“Overall, we’re seeing a really strong effect to reducing any infection, asymptomatic and symptomatic,” PHE’s strategic response director Susan Hopkins told a media briefing.

PHE’s head of immunisation Mary Ramsay described the data as “strong evidence that the Pfizer-BioNTech vaccine is stopping people from getting infected, while also protecting cases against hospitalisation and death”.

“We should be very encouraged by these initial findings,” she said.

PHE’s findings came from two separate analyses - one is an ongoing study in healthcare workers, and the second is an assessment of testing data in people aged 80 and over.

Evidence from the elderly group showed that one dose of the Pfizer shot is 57 per cent effective against symptomatic Covid-19 disease, PHE said, and early data suggest the second dose improves protection to more than 85 per cent.

“Hospitalisation and deaths rates are falling in all age groups, but the oldest age groups are seeing the fastest decline since the peak in mid-January,” a PHE statement said.

The vaccine also provides protection against the so-called British variant of the SARS-CoV-2 coronavirus, it added.

The PHE data come as preliminary study findings from Scotland on Monday also showed the vaccination drive there is working, markedly reducing the risk of hospitalisation for Covid-19.

Scottish researchers said those findings suggested that both the Pfizer and the Oxford-AstraZeneca Covid-19 vaccines are highly effective in preventing severe infections.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less